China SFDA Streamlines Approval Process For AIDS, Cancer Drug Imports (China)
This article was originally published in PharmAsia News
Executive Summary
China's State FDA says it is taking steps to remove some of the country's barriers to importation of cancer drugs, and of HIV/AIDS drugs in the wake of new infection figures. Drug registration Director Zhang Wei said the SFDA has adopted a streamlined approach to approving imports of drugs in the two categories, if they demonstrate significant clinical effects in treating disease. Under the policy, the agency cuts its 150 working days for approving most drugs to just 120 for an AIDS drug. Zhang also said U.S. company Gilead's Viread (tenofovir disoproxil fumarate) second-line anti-retroviral drug cocktail is under review. (Click here for more
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.